Overview

PF-00489791 For The Treatment Of Raynaud's

Status:
Completed

Trial end date:
2011-05-31

Target enrollment:

Participant gender:

Summary

The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Phosphodiesterase 5 Inhibitors